Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ChemoFx® PRO - A Post-Market Data Collection Study Utilizing Physician Reported Outcomes

NCT00669422 is registered in ClinicalTrials.gov with Precision Therapeutics as lead sponsor.

NCT NCT00669422
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00669422 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ChemoFx® PRO - A Post-Market Data Collection Study Utilizing Physician Reported Outcomes
Lead sponsor
Precision Therapeutics
Phase
Observational
Overall status
Terminated
Start date
October 31, 2006
Completion date
October 31, 2012
Enrollment
2,756 (actual)
Sites
67

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, endometrial cancer, fallopian tube cancer, ovarian cancer, peritoneal cancer, uterine neoplasms, vaginal cancer, vulvar cancer